RM1DA055437
Project Grant
Overview
Grant Description
Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME) - Abstract
Chronic pain (CP) and opioid use disorder (OUD) are leading causes of morbidity and mortality in the United States. Despite being commonly comorbid, there is a striking lack of integrated treatments accessible to people in need. This is particularly true for Black and Hispanic individuals living and seeking care in under-resourced settings like the Bronx, NY, one of the poorest and most racially diverse counties in the U.S.
Submitted in response to the HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) RFA-DA-21-030, the overall goal of this proposal is to create the IMPOWR Research Center at Montefiore/Einstein ("IMPOWR-ME"), in the high-impact county of the Bronx, NY. IMPOWR-ME is a synergistic multidisciplinary research center that leverages exceptional research infrastructure in CP and OUD and existing relationships with people living with CP and OUD, advocates, policymakers and payers, and health system stakeholders.
The aims of IMPOWR-ME are to:
1) Create a robust and sustainable research infrastructure to rigorously test and disseminate integrated and cost-effective evidence-based practices for people with CP and OUD.
2) Partner with people with lived experience with CP, OUD, or both, and diverse stakeholders in all stages of the research.
3) Provide opportunities for multidisciplinary early-stage investigators to become independent researchers focusing on CP and OUD.
Three innovative hybrid type 1 effectiveness-implementation trials are proposed to rigorously examine multi-modal evidence-based practices in diverse healthcare settings and populations of people with comorbid CP and OUD. Specifically, we propose:
1) A three-arm trial of yoga and physical therapy onsite at methadone opioid treatment programs.
2) A 2x2 factorial trial to test acceptance and commitment therapy and a care management smartphone app for individuals in primary-care based buprenorphine treatment.
3) A two-arm trial to test microdosing vs. standard induction of buprenorphine for hospitalized patients.
Participants in all projects have both CP and OUD or opioid misuse, and specific aims for each project will examine CP, OUD, implementation, and cost-effectiveness outcomes. Additional patient-centered outcomes will be driven by people with lived experience. All three projects improve access to care for Black and Hispanic individuals in under-resourced settings by bringing integrated treatment of CP and OUD to them, and the interventions have high potential for dissemination and sustainability.
An innovative program for pilot studies achieves a dual aim of catalyzing stakeholder-driven research and training early-stage and new investigators. An exceptional team of investigators and clinical experts focused on CP and OUD, a longstanding history of collaboration with stakeholders and people with lived experience, and a high-impact population make Montefiore-Einstein an ideal site for an IMPOWR Research Center.
Chronic pain (CP) and opioid use disorder (OUD) are leading causes of morbidity and mortality in the United States. Despite being commonly comorbid, there is a striking lack of integrated treatments accessible to people in need. This is particularly true for Black and Hispanic individuals living and seeking care in under-resourced settings like the Bronx, NY, one of the poorest and most racially diverse counties in the U.S.
Submitted in response to the HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) RFA-DA-21-030, the overall goal of this proposal is to create the IMPOWR Research Center at Montefiore/Einstein ("IMPOWR-ME"), in the high-impact county of the Bronx, NY. IMPOWR-ME is a synergistic multidisciplinary research center that leverages exceptional research infrastructure in CP and OUD and existing relationships with people living with CP and OUD, advocates, policymakers and payers, and health system stakeholders.
The aims of IMPOWR-ME are to:
1) Create a robust and sustainable research infrastructure to rigorously test and disseminate integrated and cost-effective evidence-based practices for people with CP and OUD.
2) Partner with people with lived experience with CP, OUD, or both, and diverse stakeholders in all stages of the research.
3) Provide opportunities for multidisciplinary early-stage investigators to become independent researchers focusing on CP and OUD.
Three innovative hybrid type 1 effectiveness-implementation trials are proposed to rigorously examine multi-modal evidence-based practices in diverse healthcare settings and populations of people with comorbid CP and OUD. Specifically, we propose:
1) A three-arm trial of yoga and physical therapy onsite at methadone opioid treatment programs.
2) A 2x2 factorial trial to test acceptance and commitment therapy and a care management smartphone app for individuals in primary-care based buprenorphine treatment.
3) A two-arm trial to test microdosing vs. standard induction of buprenorphine for hospitalized patients.
Participants in all projects have both CP and OUD or opioid misuse, and specific aims for each project will examine CP, OUD, implementation, and cost-effectiveness outcomes. Additional patient-centered outcomes will be driven by people with lived experience. All three projects improve access to care for Black and Hispanic individuals in under-resourced settings by bringing integrated treatment of CP and OUD to them, and the interventions have high potential for dissemination and sustainability.
An innovative program for pilot studies achieves a dual aim of catalyzing stakeholder-driven research and training early-stage and new investigators. An exceptional team of investigators and clinical experts focused on CP and OUD, a longstanding history of collaboration with stakeholders and people with lived experience, and a high-impact population make Montefiore-Einstein an ideal site for an IMPOWR Research Center.
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding Agency
Place of Performance
Bronx,
New York
10461
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 07/31/23 to 07/31/26 and the total obligations have increased 94% from $5,132,814 to $9,932,927.
Albert Einstein College Of Medicine was awarded
Integrated Care for Chronic Pain and Opioid Use Disorder: IMPOWR-ME
Project Grant RM1DA055437
worth $9,932,927
from the National Institute of Neurological Disorders and Stroke in September 2021 with work to be completed primarily in Bronx New York United States.
The grant
has a duration of 4 years 10 months and
was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs.
The Project Grant was awarded through grant opportunity HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required).
Status
(Ongoing)
Last Modified 3/5/25
Period of Performance
9/30/21
Start Date
7/31/26
End Date
Funding Split
$9.9M
Federal Obligation
$0.0
Non-Federal Obligation
$9.9M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for RM1DA055437
Transaction History
Modifications to RM1DA055437
Additional Detail
Award ID FAIN
RM1DA055437
SAI Number
RM1DA055437-135202431
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N600 NIH National Insitute on Drug Abuse
Funding Office
75NQ00 NIH National Institute of Neurological Disorders and Stroke
Awardee UEI
H6N1ZF5HJ2G3
Awardee CAGE
87UV8
Performance District
NY-14
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Health and Human Services (075-0886) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,374,098 | 57% |
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,054,073 | 43% |
Modified: 3/5/25